Lymphoma survivors' experience of participation in a home-based intervention post-chemotherapy

Autor: R. Pettengell, Hannah Moir, Suchita Hathiramani, Ahmed Younis

Publikováno v: Quality of Life Research

Purpose Further research on patient experience and involvement is recommended in order to develop evidence-based and meaningful care pathways for lymphoma survivors. This study aims to explore the experience of a sample of lymphoma survivors particip

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24d63b7da7ba0ea6dc71f8edd1c74f81
https://eprints.kingston.ac.uk/id/eprint/43632/1/Hathiramani-S-43632-VoR.pdf

Final results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: improved event-free and progression-free survival with Rituximab plus Chlorambucil versus either Chlorambucil or Rituximab monotherapy

Autor: Corinne Haioun, Maurilio Ponzoni, Pierre Zachee, Hervé Tilly, Caterina Stelitano, Catherine Thieblemont, Monica Bellei, Stefan Hohaus, Peter Johnson, Gilles Salles, Catherine Sebban, Emanuele Zucca, Franck Morschhauser, Umberto Vitolo, Valter Torri, Annarita Conconi, R. Pettengell, Reda Bouabdallah, Andrés J.M. Ferreri, André Bosly, Alessandra Tucci, Maurizio Martelli, Elias Campo, Anne Moreau, Armando Lopez Guillermo, Franco Cavalli, Liliana Devizzi, Luca Mazzucchelli, Andrew Jack, Graziella Pinotti, Giovanni Martinelli

Purpose There is no consensus on the optimal systemic treatment of patients with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. The IELSG-19 phase III study, to our knowledge, was the first such study to address the question

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bc4a08f2e8e85edb7e1facd6950153a
https://eprints.soton.ac.uk/412660/

Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma

Autor: Nicholas Counsell, Sally F. Barrington, Peter Hoskin, Paul Smith, John Radford, Dominic Culligan, Alison Brownell, R. Pettengell, Peter Johnson, Andrew Lister, Jennie Z Wimperis, Andrew McMillan, Anton Kruger, Barry W. Hancock, Michael O'Doherty, Bilyana Popova, Timothy M Illidge

Publikováno v: Radford, J, Illidge, T, Counsell, N, Hancock, B, Pettengell, R, Johnson, P, Wimperis, J, Culligan, D, Popova, B, Smith, P, McMillan, A, Brownell, A, Kruger, A, Lister, A, Hoskin, P, O'Doherty, M & Barrington, S 2015, ' Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma ', New England Journal of Medicine, vol. 372, no. 17, pp. 1598-1607 . https://doi.org/10.1056/NEJMoa1408648

It is unclear whether patients with early-stage Hodgkin's lymphoma and negative findings on positron-emission tomography (PET) after three cycles of chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) require radiotherapy.Pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89fe299ac2b0808bbc240e41fc60cc1a
https://pubmed.ncbi.nlm.nih.gov/26583613

Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis

Autor: T.C.M. ‘Curly’ Morris, Oonagh Sheehy, R Pettengell, Mark Catherwood

Publikováno v: Leukemia & Lymphoma. 50:1389-1391

Primary cutaneous CD30 positive anaplastic large cell lymphoma accounts for around 8% of T cell skin lymphomas [1]. Lesions are usually localized, only 20% of cases have multicentric cutaneous dise...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4214983e9cfe65ee5da6076230637336
https://doi.org/10.1080/10428190903045385

Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost

Autor: LS Dobson, G. R. Morgenstern, J. H. Scarffe, Derek Crowther, John Radford, W. D. J. Ryder, R. Pettengell, T. Huq, Siow Ming Lee

Publikováno v: University of Manchester-PURE
British Journal of Cancer

In order to evaluate the potential clinical and economic benefits of granulocyte colony-stimulating factor (G-CSF, filgrastim) following peripheral blood progenitor cells (PBPC) rescue after high-dose chemotherapy (HDCT), 23 consecutive patients aged

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a8bc3de8d4f03cda738d329b4b3b278
https://doi.org/10.1038/bjc.1998.216